http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Design and Assembly of a Thin-Film-Based Micro Pump for a Micro-Slot Die
Hu-Seung Lee,Dong-Wook Kwak,Jung-Ho Park,Sin Kwon,Minyang Yang 한국정밀공학회 2020 International Journal of Precision Engineering and Vol.21 No.12
In printed electronics, coating is a key process used not only in the fabrication of solar cell and organic light-emitting diodes but also in display devices. For this purpose, coating devices are designed with several unique characteristics. In particular, slot die coaters and inkjet coaters are advantageous in terms of high-quality morphology and a small dispensing area, respectively. This study proposes a slot die with a narrow-width coating as a fusion device derived from a slot die coater and an inkjet printer. This device is termed a micro-slot die and comprises a micro pump and a narrow-width slot. The device was designed and assembled with appropriate consideration of both dynamic and fluid motions. Consequently, the fabricated device achieves a high-quality coating suitable for application in the display industry. The proposed device is expected to be used in laboratory-scale research applications that require a minimal coating of ink.
Glass/phenol 복합적층판의 저속충격 특성-온도의 영향
김후식(Hu Shik Kim),김재훈(Jae Hoon Kim),이영신(Young Sin Lee),한영욱(Young Uk Han),박병준(Byoung Joon Park),안병욱(Byoung Wook An) 대한기계학회 2002 대한기계학회 춘추학술대회 Vol.2002 No.5
In this study. low velocity impact tests and compression-after-impact(CAI) tests have been used to evaluate the effect of temperature on the low velocity impact characteristics of phenol-matrix composites reinforced with woven glass-fabric. Drop weight(low velocity) impact causes three principle types of damage in laminates. namely matrix cracking, delamin-ation, and fiber breakage, which together can seriously degrade residual compressive strength in laminates. The distribution of impact damage for the various temperature. can be determined from ultrasonic C-scan images. and the shape of damage is approximately elliptical. The damage area increases with increasing temperature and impact energy. All these observation indicate reduced impact damage tolerance of the laminates at evaluted temperature.
YHB216 의 비글개에서 정맥내 단회 및 4 주 반복투여독성시험
장호송(Hu Song Zhang),정은용(Eun Yong Jung),신지순(Ji Soon Sin),안경규(Kyoung Kyu Ahn),최연식(Yeon Shik Choi),강종구(Jong Koo Kang),노용우(Yong Woo Roh),지형진(Hyeong Jin Ji),강민정(Min Joung Kang),이종욱(Jong Wook Lee) 한국응용약물학회 2002 Biomolecules & Therapeutics(구 응용약물학회지) Vol.10 No.1
N/A Recently, recombinant human erythropoietin (rHu-EPO) has been used to treat various types of anemia. YHB216 is a new rHu-EPO developed by Yuhan Research Institute. In this study, we investigated the single dose and 4-week repeated dose toxicity of YHB216 in Beagle dogs. In the single dose toxicity study, YHB216 was administered intravenously at single dose levels of 0 and 25,000 IU/㎏ to dogs (2 dogs/sex/ group). There were no treatment-related changes in survivals, clinical signs, body weight gain, hematological values, blood chemical values, and necropsy finding during experimental period. In the repeated dose toxicity study, YHB216 was administered intravenously to dogs for 4 weeks at the dose levels of 0, 100, 500, and 2,500 IU/㎏ (3 dogs/sex/group). There were no toxicologically significant changes in clinical signs, body weights, food and water consumptions, ophthalmoscopy, urinalysis and blood chemistry. There were increased values of red blood cell, hemoglobin, and hematocrit at all treated groups. Spleen revealed increased weight and extramedullary hematopoiesis at 500 IU/㎏ or more. These changes are all considered to be pharmacology-related effects and were recovered after 4-week recovery period. From these results, it is concluded that LD_50 value was above 25,000 IU/㎏ in the single dose toxicity study of YHB216 in dogs and the no observed adverse effect level (NOAEL) was 100 IU/㎏/day in the repeated dose toxicity study of YHB216 in dogs.
이후경,손기호,민일기,신완균,최경업,서옥경 韓國病院藥師會 2004 병원약사회지 Vol.21 No.1
Hospital drug formulary is a continually revised compilation of pharmaceuticals, reflecting the current clinical judgement of medical staffs. This study was conducted to evaluate the appropriateness of hospital formulary in Korea. Out of 113 hospitals with more than 400 beds, 20 hospitals published formularies in 2002. Fifteen hospital formularies out of 20 were obtained for evaluation. Hospitals being surveyed were categorized by the number of beds(greater than 700 beds vs. 400~699 beds) and by the type of hospital(tertiary vs. acute care hospital). The criteria for formulary content and organization suggested by American Society of Health System Pharmacist(ASHP) was modified and applied. Drugs were categorized based on both the drug classifications suggested by Ministry of Health and Welfare and Drug Facts and Comparisons. Formularies were revised annually or biannually in 51 out of 113 hospitals(45.2%). Of 15 hospitals studied, 8 were tertiary hospitals(53%) and 7 had greater than 700 beds. Information on organizational policies and procedures concerning drugs and using the formulary were provided in all 15 hospitals. However, restrictions on drug use and procedures for requesting a drug to be added to the formulary were included in only one hospital. Drug products were listed alphabetically by generic name in all 15 hospitals. Generic name of the drug, dosage form(s), strength(s), packing(s), size(s) and formulation(active ingredient) of a combination product, and drug classification number were provided in all 15 hospitals. Among special information, comparison of amino acid solutions, skin tests, stability of antineoplastic and antibiotic agents, pediatric dosing, and pregnancy categories were included in more 50% of the hospitals. However, the number of drugs in the formularies from Korean hospitals were higher than those from other countries. Evaluation of hospital formulary was attempted for the first time in Korea and this could be applied as a guideline to the hospitals preparing formulary publication and update. Also, the selection of items to be included in the formulary should be based on objective evaluation of their relative therapeutic merits, safety, and cost.